Table 5 Associations between APOE ε4 genotypes and echocardiographic data in older age by comparing non-APOE ε4 (ε2ε2, ε2ε3, ε2ε3) with heterozygous-APOE ε4 (ε2ε4 and ε3ε4) and homozygous-APOE ε4 (ε4ε4) genotypes
From: APOE ε4 carriage associates with improved myocardial performance from adolescence to older age
Model 1 (unadjusted) | Model 2 (adjusted for sex and SEP) | Model 3 (Model 2 + BMI) | Model 4 (Model 2 + CVD) | Model 5 (Model 2 + diabetes) | Model 6 (Model 2 + high cholesterol) | Model 7 (Model 2 + HT) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Outcome: | Cohort | Analysis | n | Exp β (95% CI) | p-value | Exp β (95% CI) | p-value | Exp β (95% CI) | p-value | Exp β (95% CI) | p-value | Exp β (95% CI) | p-value | Exp β (95% CI) | p-value | Exp β (95% CI) | p-value |
MCF | UK Biobank | Heterozygous-APOE ε4 | 31,909 | 1.01 (1.00, 1.01) | 0.047 | 1.00 (0.99, 1.01) | 0.140 | 1.00 (1.00, 1.01) | 0.120 | 1.01 (1.00, 1.01) | 0.019 | 1.00 (1.00, 1.01) | 0.116 | 1.01 (1.00, 1.01) | 0.0008 | 1.00 (1.00, 1.01) | 0.069 |
SABRE + NSHD meta-analysis | Heterozygous-APOE ε4 | 2019 | 1.04 (1.01, 1.07) | 0.016 | 1.04 (1.01, 1.07) | 0.013 | 1.04 (1.01, 1.07) | 0.018 | 1.03 (1.00, 1.06) | 0.043 | 1.03 (1.00, 1.07) | 0.060 | 1.05 (1.00, 1.10) | 0.040 | 1.03 (1.00, 1.06) | 0.028 | |
ALSPAC | Heterozygous-APOE ε4 | 1328 | 1.02 (1.00, 1.05) | 0.066 | 1.02 (0.99, 1.04) | 0.236 | 1,03 (1.00, 1.05) | 0.039 | 1.02 (1.00, 1.05) | 0.067 | 1.02 (0100, 1.05) | 0.069 | 1.03 (1.00, 1.06) | 0.079 | 1.02 (0.99, 1.05) | 0.169 | |
UK Biobank | Homozygous-APOE ε4 | 25,086 | 1.01 (1.00, 1.03) | 0.083 | 1.01 (1.00, 1.02) | 0.166 | 1.01 (1.00, 1.02) | 0.252 | 1.01 (1.00, 1.03) | 0.034 | 1.01 (1.00, 1.02) | 0.115 | 1.02 (1.01, 1.03) | 0.006 | 1.01 (1.00, 1.02) | 0.123 | |
SABRE + NSHD meta-analysis | Homozygous-APOE ε4 | 1539 | 1.03 (0.95, 1.11) | 0.544 | 1.03 (0.95, 1.11) | 0.517 | 1.04 (0.96, 1.13) | 0.350 | 1.02 (0.92, 1.10) | 0.704 | 1.01 (0.93, 1.09) | 0.874 | 1.01 (0.92, 1.11) | 0.812 | 1.02 (0.94, 1.10) | 0.652 | |
ALSPAC | Homozygous-APOE ε4 | 998 | 1.00 (0.96, 1.05) | 0.984 | 1.01 (0.97, 1.06) | 0.588 | 1.00 (0.96, 1.05) | 0.892 | 1.00 (0.96, 1.05) | 0.984 | 1.00 (0.96, 1.05) | 0.935 | 0.99 (0.95, 1.04) | 0.701 | 1.00 (0.95, 1.06) | 0.920 | |
Longitudinal PDSR | UK biobank | Heterozygous-APOE ε4 | 31,909 | 1.02 (1.00, 1.03) | 0.049 | 1.00 (0.99, 1.02) | 0.610 | 1.02 (1.00, 1.03) | 0.059 | 1.02 (1.00, 1.03) | 0.038 | 1.01 (1.00, 1.03) | 0.099 | 1.02 (1.01, 1.04) | 0.004 | 1.02 (1.00, 1.03) | 0.062 |
UK biobank | Heterozygous-APOE ε4 | 24,965 | 1.01 (0.97, 1.06) | 0.556 | 1.00 (0.96, 1.04) | 0.843 | 1.01 (0.96, 1.05) | 0.754 | 1.02 (0.97, 1.06) | 0.469 | 1.01 (0.97, 1.06) | 0.679 | 1.03 (0.98, 1.08) | 0.206 | 1.01 (0.97, 1.06) | 0.631 | |
Radial PDSR | UK biobank | Heterozygous-APOE ε4 | 31,773 | 0.95 (0.90, 1.00) | 0.049 | 0.98 (0.93, 1.03) | 0.467 | 0.96 (0.90, 1.01) | 0.094 | 0.94 (0.89, 1.00) | 0.035 | 0.96 (0.91, 1.01) | 0.097 | 0.93 (0.88, 0.98) | 0.005 | 0.95 (0.90, 1.00) | 0.058 |
UK biobank | Heterozygous-APOE ε4 | 24,965 | 0.97 (0.83, 1.14) | 0.726 | 1.02 (0.88, 1.18) | 0.772 | 0.98 (0.84, 1.15) | 0.820 | 0.96 (0.82, 1.12) | 0.605 | 0.99 (0.85, 1.15) | 0.859 | 0.93 (0.80, 1.08) | 0.327 | 0.98 (0.84, 1.14) | 0.789 | |